baber/WOPTO huggingface dataset:
Patent NZ-595781-A (NZ)
Title: Fused pyrimidine derivatives as trpv3 modulators
Inventor: LINGAM V S PRASADARAO
IPC: C07D471/04
Filed: 2009-01-07
Abstract: Disclosed herein are fused pyrimidine compounds of formula (I), wherein the substituents are as defined within the specification; processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful the their Transient Receptor Potential Vanilloid 3 (TRPV3) activity and as such are useful in the treatement of pain, acute pain, chronic pain, nociceptive pain, neuropathic pain, post-operative pain, dental pain, cancer pain, cardiac pain arising from an ischemic myocardium, pain due to migraine, arthralgia, neuropathies, neuralgia, trigeminal neuralgia nerve injury, diabetic neuropathy, neurodegeneration, retinopathy, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, urinary incontinence, vulvodynia, gastrointestinal disorders such as irritable bowel syndrome, gastro-esophageal reflux disease, enteritis, ileitis, stomach-duodenal ulcer, inflammatory bowel disease, Crohn's disease, celiac disease, an inflammatory disease such as pancreatitis, a respiratory disorder such as allergic and non-allergic rhinitis, asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, dermatitis, pruritic conditions such as uremic pruritus, fervescence, muscle spasms, emesis, dyskinesias, depression, Huntington's disease, memory deficits, restricted brain function, amyotrophic lateral sclerosis (ALS), dementia, arthritis, osteoarthritis, diabetes, obesity, urticaria, actinic keratosis, keratocanthoma, alopecia, Meniere's disease, tinnitus, hyperacusis, anxiety disorders and benign prostate hyperplasia.
Patent NZ-597947-A (NZ)
Title: Klotho-beta for use in treating cancer, liver disorders, wasting syndrome and obesity-related diseases
Inventor: DESNOYERS LUC
IPC: A61K38/17
Filed: 2008-04-01
Abstract: Disclosed is the use of Klotho beta modulating antibodies in the treatment of diabetes, cardiovascular disease, insulin resistance, hypertension, thromboembolic disease and dyslipidemia. Disruption of the gene encoding KL-? results in marked increases in mRNA levels of cholesterol 7alpha-hydroxylase (CYP7A1), the first and rate-limiting enzyme in the bile acid biosynthetic pathway.
Patent NZ-600040-A (NZ)
Title: Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method.
Inventor: SIRANITA AKIO
IPC: A61K38/00
Filed: 2010-11-26
Abstract: 600040 Disclosed herein is a method for screening a drug which is efficacious in treating dry eye with a dry eye severity level 3 or higher that is defined in 2007 report of the International Dry Eye Workshop and/or keratoconjunctival disorders. The method comprises preparing a rabbit model of corneal and conjunctival lesion having corneal and conjunctival epithelial abrasion by instilling n-heptanol solution optionally including ethanol to an eye of a rabbit; and administering a test agent to the eye of the rabbit model and determining an effect of restoring corneal tissue of the test agent, wherein the conditions of cornea and conjuctiva are observed with a dye such as fluorescein.
Patent NZ-601434-A (NZ)
Title: Reclosable packaging using a low-tack adhesive fastener
Inventor: ZERFAS PAUL ANTHONY
IPC: B31B50/00
Filed: 2012-07-24
Abstract: 601434 A flexible film package (20) having an adhesive based reclosable fastener having a flexible film substrate (25) forming a plurality of package walls (21, 22, 23, 24) sealed to form an interior cavity for receiving a product; the plurality of walls having at least two opposing flexible walls (22, 24); a package mouth (27), initially sealed, to permit access to the interior cavity; a low tack pressure sensitive adhesive (LTPSA) layer (26, 28) disposed on each of an exterior surface of the parallel walls, the LTPSA sized and oriented in positions to oppose one another at a plurality of positions when the package is reclosed to allow progressively decreased size of the interior cavity as product is removed; and wherein a bond strength of the LTPSA to the flexible film substrate is greater than an adhesion between LTPSA areas. The mouth can be formed by a peelable seal or by a defined area of weakness.
Patent NZ-602551-A (NZ)
Title: Genetic marker for the diagnosis of dementia with lewy bodies
Inventor: DOMINGO SABAT MONTSERRAT
IPC: C12Q1/68
Filed: 2011-02-24
Abstract: 602551 Disclosed is an in vitro method for the diagnosis of dementia with Lewy bodies comprising determining in a biological sample from a subject, the genotype of the following alterations in butyrylcholinesterase (BChE) gene, or of polymorphisms in linkage disequilibrium thereof: the polymorphic site at position 68974 in NCBI Accession Number NG_009031 (i.e. position 934 in SEQ ID NO: 28); and the poly-thymine region at positions 4780 to 4786 in NCBI Accession Number NG_009031 (i.e. positions 4780-4786 in SEQ ID NO: 1). Further disclosed is a use of the polymorphic site at position 68974 in NCBI Accession Number NG_009031 (i.e. position 934 in SEQ ID NO: 28), in combination with the following alteration in BChE gene consisting of the poly-thymine region at positions 4780 to 4786, the polymorphic site at position 3687; the polymorphic site at position 4206; and the polymorphic site at position 4443, as a marker for the diagnosis of dementia with Lewy bodies, said positions with reference to NCBI Accession Number NG_009031 (i.e. positions 3687, 4206, 4443 and 4780-4786 respectively in SEQ ID NO: 1).
Patent NZ-602957-A (NZ)
Title: Pharmaceutical composition of ibuprofen for injection
Inventor: ORTUZAR ANDECHAGA IGNACIO
IPC: A61K9/10
Filed: 2011-05-18
Abstract: Disclosed is a pharmaceutical composition of ibuprofen for injection comprising an aqueous solution of ibuprofen and trometamol (tris / tris(hydroxymethyl)aminomethane / 2-amino-2-hydroxymethyl-propane-1,3-diol), wherein the concentration of ibuprofen is between 2 and 6 mg/ml, the concentration of trometamol is between 1.8 and 5.8 mg/ml, and the pH is between 7.0 and 9.5, wherein the composition can be sterilised by heat by autoclaving at a temperature between 110°C and 130°C for a time between 2 and 190 minutes, and wherein the composition is for use in the treatment of pain, inflammation or fever.
Patent NZ-604402-A (NZ)
Title: Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan
Inventor: KIM MIN JUNG
IPC: A61P3/06
Filed: 2011-05-13
Abstract: Disclosed is a pharmaceutical formulation in the form of a tablet comprising: a) a first layer containing irbesartan (2-butyl-3-({ 4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl} methyl)-1,3-diazaspiro[4.4]non-1-en-4-one) or a pharmaceutically acceptable salt thereof; and b) a second layer containing an HMG-CoA reductase inhibitor (for example atorvastatin), and a basic additive such as sodium bicarbonate (NaHCO3) or magnesium carbonate (MgCO3). Formulation is useful for treating hypertension and hypercholesterolemia.
Patent NZ-608395-A (NZ)
Title: Transportation and display box
Inventor: ORGELDINGER WOLFGANG
IPC: B65D85/30
Filed: 2010-09-20
Abstract: A box (10) is disclosed comprising a floor (12) and at least two pairs of opposing side walls (14a, 14b, 16a, 16b). One of the side walls (16b) extends upwards from the floor (12) in a vertical direction (18) by a retrieval height (20) which is lower than the height of one or several of the remaining side walls (14a, 14b, 16a). The lower wall (16b) defines a lateral opening which enables access to products contained in the box. An insert (22a, 22b) is arranged on the floor (12) of the box to position items which are received in the box. The side walls (16a, 16b) have grip openings (28a, 28b) for lifting the box, a first part of the opening extends parallel to the floor and a second part extends vertically forming a comfortable grip which allows the box to be tilted.
Patent NZ-614130-A (NZ)
Title: Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Inventor: WILSON JO ANN
IPC: C07D215/233
Filed: 2012-02-10
Abstract: Disclosed herein are pharmaceutical compositions of the compound N-(4-{ [6,7-bis(methoxyquinolin-4-yl]oxy} phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and the (L)-malate salt thereof, wherein the formation of 6,7-dimethoxy-quinoline-4-ol in the pharmaceutical formulation is minimized to 50 ppm or less over time.
Patent NZ-614215-A (NZ)
Title: Compositions and methods for the therapy and diagnosis of influenza
Inventor: GRANDEA ANDRES G
IPC: A61P31/16
Filed: 2012-02-14
Abstract: Disclosed is a composition comprising (a) an isolated human antibody that specifically binds to an epitope of the hemagglutinin (HA) glycoprotein of an influenza virus; and (b) an isolated human monoclonal antibody that specifically binds to an epitope in the extracellular domain of the matrix 2 ectodomain (M2e) polypeptide of an influenza virus; wherein the antibodies comprise the VH/VL chains or CDRs of the sequences as defined in the specification.
Patent NZ-620212-A (NZ)
Title: Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
Inventor: GUILLEMONT JERÔME EMILE GEORGES
IPC: C07D487/04
Filed: 2012-08-10
Abstract: The present disclosure is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
Patent NZ-624106-A (NZ)
Title: Apparatus and method for replacing a diseased cardiac valve
Inventor: NAVIA JOSE LUIS
IPC: A61F2/24
Filed: 2010-04-28
Abstract: An apparatus for replacing a native cardiac valve that has at least one leaflet and is surrounded by a native cardiac valve annulus with a superior aspect and an inferior aspect. The apparatus 10 includes an expandable anchoring member 42 with a central cylindrical portion including a channel 50 and end portions 44, 46 that contact the superior and inferior aspects of the native valve annulus when the expandable anchoring member is in the expanded condition. An expandable support member 56 is movable from a radially collapsed configuration to a radially expanded configuration, and having a first end portion, a second end portion and a main body portion extending between the first and second end portions and fastened into the channel 50 of the anchoring member using fasteners. A prosthetic cardiac valve 50 is operably secured within the main body portion of the expandable support member 56.
Patent NZ-625776-A (NZ)
Title: Herbicidal composition containing certain pyridine carboxylic acids and (2,4-dichlorophenoxy)acetic acid
Inventor: OVALLE DANIEL
IPC: A01N43/40
Filed: 2012-12-05
Abstract: Herbicidal compositions comprising 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid (I) or a derivative thereof and 2,4-D (2,4-Dichlorophenoxyacetic acid) or a derivative thereof. Also disclosed is a method of controlling undesirable vegetation such as Melochia, Eleusine, Lolium, Panicum, MEOPA, ELEIN, LOLMU, or PANDI.
Patent NZ-625952-A (NZ)
Title: A lock assembly with electrically adjusted coupling
Inventor: CRAIG ANTHONY CASPERSZ
IPC: E05B47/00
Filed: 2014-06-05
Abstract: Disclosed is a lock assembly for use in controlling retraction of a latchbolt relative to a door. The assembly includes an outer body (3) for location on an outer side of the door and an outer (12) hand operable member rotatable relative to the outer body (3) for retracting the latchbolt. A disengagable coupling mechanism interacts between the outer hand operable member (12) and the latchbolt and adjustable between an engaged condition and a disengaged condition to render the outer hand operable member (12) operable or inoperable respectively. An electrically powered detent means (31) interacts with the coupling mechanism and is adjustable between an active condition and an inactive condition to render the coupling mechanism disengaged or engaged respectively. The handle can be turned from a left hand to a right hand position.
Patent NZ-627455-A (NZ)
Title: Concrete bridge system and related methods
Inventor: ASTON SCOTT D
IPC: E03F1/00
Filed: 2013-01-31
Abstract: A concrete culvert (10) with tapered legs (16) is described. The system includes: a top wall (14); and two planar side walls (16) which decrease in thickness from top to bottom. The components join at haunches (28) which are thicker than the respective walls. The configuration seeks to minimize the concrete required to form a tunnel (18) beneath the arch.
Patent NZ-701915-A (NZ)
Title: High-concentration monoclonal antibody formulations
Inventor: ARMSTRONG NICHOLAS J
IPC: A61K39/395
Filed: 2013-05-17
Abstract: The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle where the viscocity of the suspension vehicle is less than about 20 centipoise at about 20˚C, and wherein the non-aqueous suspension vehicle comprises ethyl lactate. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.
Patent NZ-703108-A (NZ)
Title: Tag line extension
Inventor: COTTONE SHAUN
IPC: B66F19/00
Filed: 2013-06-05
Abstract: A tag line extension adapted to be attached to a load, the tagline extension comprising: (i) a rigid arm defining a base and a free end adapted to receive a tag line, the rigid arm being movable from a first position to a second, deployed position at which the free end of the rigid arm is located at a lateral distance from the load; and (ii) a stop means to define the range of movement of the rigid arm between the first and second positions and hence define the second, deployed position. The tag line extension allows for the safer manual handling of suspended loads as the deployed position of the rigid arm allows an operator to handle the load without standing directly under the load at any time.
Patent NZ-707059-A (NZ)
Title: Methods of culturing microorganisms in non-axenic mixotrophic conditions
Inventor: GANUZA ENEKO
IPC: C12N1/12
Filed: 2013-11-08
Abstract: Methods of culturing microorganisms in non-axenic mixotrophic conditions are disclosed. A method of culturing microalgae mixotrophically and controlling bacterial contamination with an acetic acid/pH auxostat system is specifically described. The pH auxostat system is activated with an initial concentration of sodium acetate to start supplying acetic acid at a concentration of 15-50% (v/v) to the culture wherein the pH auxostat system operates within 6-9 and the temperature ranges from 10 ºC-30 ºC. Methods of culturing microalgae mixotrophically with an increased productivity through an increase in oxygen transfer to the culture, and controlling bacterial contamination with an oxidative agent are also described. By supplying light for between 10-16 hours in each 24 hour day and supplying no light for the remaining 8-14 hours in the same 24 hour day, microalgae can be cultured in non-axenic mixotrophic conditions with increased productivity compared to a continuous light supply and with less bacterial contamination.
Patent NZ-709566-A (NZ)
Title: Hangi oven
Inventor: BROWN RAWHITI
IPC: A47J27/04
Filed: 2018-08-27
Abstract: The invention relates to an oven for cooking food according to the hangi method. The invention provides an oven which is able to impart a true hangi flavour into food cooked within it. The hangi oven described is made of untreated steel which is an important feature in imparting the true hangi flavour into the food. The flavour imparted by the invention is very similar to the flavour gained by food that is cooked in the ground in the traditional hangi method. However the invention provides a much easier way of cooking food than by the traditional method which is labour intensive.
Patent NZ-709729-A (NZ)
Title: Nasal assembly
Inventor: DAVIDSON AARON SAMUEL
IPC: A61M16/06
Filed: 2006-10-13
Abstract: A patient interface for delivering a supply of pressurized breathable gas to a patient, comprising: a cushion configured to form a seal around an opening to a patient’s airways in use; a frame (65) connected to the cushion, the frame and the cushion together defining a chamber, the frame including a vent channel (90) defined by a connecting wall (base wall 92) and a pair of side walls (94) extending from an inside surface of the frame to the connecting wall, the connecting wall including a plurality of vent holes configured to provide gas-washout of the chamber in use; and an inlet elbow configured to join an air delivery tube with the chamber. The side walls converge towards one another in the direction of the connecting wall (at angle alpha).
Patent NZ-711083-A (NZ)
Title: Latching devices
Inventor: CHRISTOPHER JAMES ALLINGTON
IPC: A62B35/00
Filed: 2014-08-18
Abstract: Where members are in a kinematic relationship and where relative movement between the members needs to be controlled, the way that motion is controlled may not entirely stop movement altogether or instead may stop movement in a sudden manner. Described herein are latching devices where relative speed of movement between members is in part controlled or reduced via eddy current formation and in part controlled or relative motion stopped via a latch arrangement. The described latching devices slow and stop relative movement and provide redundancy should one or the other method fail.
Patent NZ-716411-A (NZ)
Title: An accessory for a weighted support assembly
Inventor: GREGORY JAMES BLOOM
IPC: F16M13/00
Filed: 2016-01-27
Abstract: An accessory for a multi weighted support assembly includes an elongate post holder that is configured to hold an elongate support post and for mounting to a weighted support assembly. A panel retaining structure is arranged on the post holder and is configured to engage adjacent panels in a side-by-side manner so that the panels can be operatively positioned with respect to a support post mounted on or in the post holder. This device is useful in that it makes it easier to erect a temporary fencing or walled panel structure. The apparatus also allows for multiple weights to be stacked thus preventing the panels from toppling from any potential wind loading.
Patent NZ-717101-A (NZ)
Title: Partial melt co-crystallization compositions
Inventor: LIAO SHYHYUAN
IPC: A61K9/14
Filed: 2014-06-24
Abstract: Preparing co-crystallization compositions, containing sugar alcohols such as erythritol as a crystallisable carrier and a high intensity sweetening active, via the partial dissolution of the crystallisable carrier in an aqueous solution before or after the addition of the sweetening active. This mix is then dried and recrystallized to form the final co-crystallization compositions. Methods of using the co-crystallization compositions are also disclosed.
Patent NZ-719137-A (NZ)
Title: Combination of two antivirals for treating hepatitis c
Inventor: WALID M AWNI
IPC: A61P31/12
Filed: 2014-03-14
Abstract: Disclosed is a method for treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient, wherein neither interferon nor ribavirin are administered to said patient during said treatment, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise: Compound 1 or a pharmaceutically acceptable salt thereof, and Compound 2 or a pharmaceutically acceptable salt thereof.
Patent NZ-720813-A (NZ)
Title: Composition and method for aiding sleep
Inventor: CHEN LAN BO
IPC: A61K47/30
Filed: 2015-02-04
Abstract: Described is a controlled-release formulation for treating disturbed sleep or insomnia. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages. In a preferred embodiment, the formulation is formulated for a first stage immediate release of diphenhydramine HCl, a second stage release of zolpidem tartrate that starts 2-3 hours after initiation of the first stage, and a third stage release of lorazepam that starts 2-3 hours after initiation of the second stage.
Patent NZ-726671-A (NZ)
Title: Compounds useful as inhibitors of atr kinase and combination therapies thereof
Inventor: POLLARD JOHN
IPC: A61P35/00
Filed: 2013-04-05
Abstract: The invention of the present application relates to compounds of formula VE-822 and their uses in the manufacture of a medicament for treating cancers having a defect in a base excision repair protein.
Patent NZ-729005-A (NZ)
Title: Aminopyrimidinyl compounds as jak inhibitors
Inventor: WAN ZHAO-KUI
IPC: C07D519/00
Filed: 2015-08-07
Abstract: A compound having the structure or a pharmaceutically-acceptable salt thereof: Formula (I). Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.
Patent NZ-733857-A (NZ)
Title: Thermostable vaccine compositions and methods of preparing same
Inventor: HASSETT KIMBERLY
IPC: A61K9/19
Filed: 2012-05-17
Abstract: The disclosure relates to a method of preparing an immunologically-active adjuvant-bound dried vaccine composition, the method comprising: combining at least one aluminum-salt adjuvant, at least one buffer system containing at least one volatile salt, at least one glass-forming agent and at least one antigen together to create a liquid vaccine formulation; freezing it to create a frozen vaccine formulation; and lyophilizing the frozen vaccine formulation in to create a dried vaccine composition. The aluminum-salt adjuvant is selected from of aluminum hydroxide, aluminum phosphate and aluminum sulfate, the volatile salt is selected from the group consisting of ammonium acetate, ammonium formate, ammonium carbonate, ammonium bicarbonate, triethylammonium acetate, triethylammonium formate, triethylammonium carbonate and the glass forming agent is selected from trehalose, sucrose, ficoll, dextran, sucrose, maltotriose, lactose, mannitol, hydroxyethyl starch, glycine, cyclodextrin, and povidone. The immunologically-active co-adjuvant may be lipid A, lipid A derivatives, monophosphoryl lipid A, chemical analogues of monophosphoryl Lipid A, CpG containing oligonucleotides, TLR-4 agonists, flagellin, flagellins derived from gram negative bacteria, TLR-5 agonists, fragments of flagellins capable of binding to TLR-5 receptors, saponins, analogues of saponins, QS-21, purified saponin fractions, ISCOMS or saponin combinations with sterols and lipids. The disclosure also relates to said vaccine composition.
Patent NZ-748137-A (NZ)
Title: A trolley mechanism for wheeled luggage
Inventor: AUSTIN KENNETH
IPC: A45C5/14
Filed: 2016-11-18
Abstract: A trolley mechanism for wheeled luggage with a trolley deck pivotally coupled to the bottom of the luggage and having a wheel at its distal end, where in a deployed configuration the luggage is upright on the luggage wheels and the distal end of the deck is pivoted away from the luggage and supported by the trolley wheel to form a support surface for additional baggage, and in a stowed configuration the deck lies against the surface of the luggage and can be held in place by a trolley handle at the top of the luggage extending through an aperture in a raised edge at the distal end of the deck, and where the pair of luggage wheels adjacent the pivot point of the trolley deck extend at an angle so as to allow the luggage to be moved using the trolley handle when upright and by a deployable sled handle when laid down on the stowed trolley deck.